|
|
News Breaks | | | | November 12, 2012 | | 15:33 EDT |  | BMY | Bristol-Myers reports data for studies of Hep C compounds
Bristol-Myers Squibb announced for the first time interim results from the global, D-LITE Phase IIb study, in which a 24-week regimen combining the investigational compound Peginterferon lambda-1a with the investigational direct-acting antiviral daclatasvir and ribavirin, achieved sustained virologic response 12 weeks post-treatment in 93%, or 13/14, of treatment-naïve, genotype 1b chronic hepatitis C patients who achieved a protocol-defined response. The SVR12 rate for all genotype 1 infected patients in the Lambda/RBV/DCV group was 76%, or 28/37. These study findings were presented in a late breaker presentation at the American Association for the Study of Liver Diseases congress in Boston. The company also presented SVR4 results from the D-LITE Japanese sub-study, where all subjects were infected with HCV genotype 1b and SVR12 was 100%. SVR results from the EMERGE Phase IIb study of Lambda versus alfa interferon in treatment-naïve genotype 1 or 4 patients were also presented. In the D-LITE study, adverse events were mostly low grade and self-limiting. In the Lambda/RBV/DCV treatment group, only one of 37 patients experienced a serious adverse event, breast cancer, which was unrelated to study drug. The lead investigator said, “Treatment with lambda interferon combined with daclatasvir and ribavirin achieved high rates of sustained virologic response, and the data support further study of regimens using lambda interferon to address the medical needs of hepatitis C patients who cannot use alfa interferons.” | |
|
News For BMY From The Last 14 Days Check below for free stories on BMY the last two weeks. |
|
|
| June 19, 2013 | | 05:43 EDT | | BMY | AstraZeneca, Bristol-Myers announce top line results of Phase 4 trial of Onglyza
 Subscribe for More Information | | | June 17, 2013 | | 07:28 EDT |  | BMY | Cambridge Healthtech Institute to host a conference
Subscribe for More Information | | | June 14, 2013 | | 09:03 EDT | | BMY | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. | | | 08:02 EDT | | BMY | Bristol-Myers, Simcere enter Orencia pact for China
Subscribe for More Information | | | June 13, 2013 | | 11:02 EDT | | BMY | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information | | | June 12, 2013 | | 13:15 EDT | | BMY | Bristol-Myers, AstraZeneca issue statement on review of some therapies
Subscribe for More Information | | | June 11, 2013 | | 18:09 EDT | | BMY | Orencia trial data shows efficacy rate comparable to Humira
Bristol-Myers announced the results of year two data from AMPLE, a trial of 646 patients comparing the subcutaneous formulation of Orencia, or abatacept, vs. Humira, or adalimumab, each on a background of MTX, in biologic naïve patients with moderate to severe RA. The AMPLE year two data are being presented this week at the European League Against Rheumatism annual congress and highlighted during a congress press conference. AMPLE met its primary endpoint as measured by non-inferiority of ACR20 at year one. The Orenica regimen achieved comparable rates of efficacy vs. the Humira regimen, or 64.8% vs. 63.4%, respectively. Onset of response was also generally similar for the two groups. Year two of the study remained investigator-blinded. At year two, the Orencia regimen achieved the same rate of efficacy as the Humira regimen based on ACR20. | | | 08:01 EDT | | BMY | Leerink's major pharma and biotech analysts hold a conference call
Subscribe for More Information | | | June 7, 2013 | | 13:49 EDT |  | BMY | Bristol-Myers volatility elevated as shares pullback from 11-year high
Subscribe for More Information | | | June 6, 2013 | | 11:04 EDT | | BMY | Bristol-Myers says Health Canada expands Abilify indications
Abilify has received an additional approval from Health Canada as an adjunct, or add-on, treatment to antidepressants for the treatment of major depressive disorder in adults who had an inadequate response to prior antidepressant treatments during the current episode. | | |
|
|
|
|
|
|
